ROCKVILLE, Md., Nov. 21, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB, the "Company"), a U.S.-based global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that management will present at the Piper Sandler 36th Annual Healthcare Conference on December 4, 2024.
Piper Sandler 36th Annual Healthcare Conference Presentation Details
Presentation Time | Wednesday, December 4 at 4:30 p.m. ET |
Presenters | Sean Fu, PhD, MBA, Chief Executive Officer Phillip Dennis, MD, PhD, Chief Medical Officer |
Webcast link | |
Meetings | One-on-one and small group meetings: December 3 – 4, 2024 |
Management | Sean Fu, PhD, MBA, Chief Executive Officer Joseph Skelton, Chief Financial Officer Phillip Dennis, MD, PhD, Chief Medical Officer Tyler Ehler, Senior Director, Investor Relations |
The webcast will also be available under "Event Calendar" on I-Mab's IR website at https://ir.i-mabbiopharma.com/
For more information, please contact your Piper Sandler representative.
About I-Mab
I-Mab (NASDAQ: IMAB) is a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer. I-Mab has established operations in Rockville, Maryland, and Short Hills, New Jersey. For more information, please visit https://www.i-mabbiopharma.com and follow us on LinkedIn and X.
For more information, please contact:
Tyler Ehler
Senior Director, Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$0.94 |
| Daily Change: | -0.04 -4.08 |
| Daily Volume: | 262,355 |
| Market Cap: | US$72.930M |
November 14, 2024 November 06, 2024 September 16, 2024 September 10, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
